The P2RY8 antibody targets the P2Y purinoceptor 8 (P2RY8), a G protein-coupled receptor (GPCR) belonging to the P2Y receptor family, which responds to extracellular nucleotides like ATP and ADP. P2RY8 is primarily expressed in immune cells, including B cells and dendritic cells, and plays a role in regulating immune responses, cell migration, and apoptosis. It signals through Gα12/13 proteins, activating Rho GTPase pathways to modulate cytoskeletal dynamics. Research has highlighted its involvement in lymphoid malignancies, particularly in diffuse large B-cell lymphoma (DLBCL), where chromosomal rearrangements or mutations in P2RY8 disrupt its tumor-suppressive functions. These genetic alterations often lead to constitutive activation of downstream oncogenic pathways, such as RHOA, promoting cell survival and proliferation. P2RY8 antibodies are critical tools for detecting receptor expression, localization, and functional alterations in both physiological and pathological contexts. They enable studies exploring P2RY8's role in immune regulation, cancer biology, and potential therapeutic targeting. Commercially available antibodies are typically validated for applications like Western blotting, immunohistochemistry, and flow cytometry, aiding in biomarker discovery and mechanistic investigations. Recent studies also suggest P2RY8 as a candidate for immunotherapy or small-molecule modulation, emphasizing its translational relevance in oncology and immunology.